The Mainz-based biotech company BioNTech is close to a breakthrough with its potential corona vaccine. BioNTech and its U.S. partner Pfizer presented positive efficacy data from the decisive study with the vaccine on Monday. According to these data, the risk of contracting Covid-19 was more than 90 percent lower for study participants who received the vaccine than without the vaccination.
BioNTech and Pfizer are thus the first companies worldwide to present successful data from the study with a corona vaccine, which is crucial for approval. “This is the first evidence that Covid-19 can be prevented by a vaccine in humans,” BioNTech CEO Ugur Sahin told Reuters.
The two partners plan to apply for emergency approval for the vaccine in the U.S. later this month. If sufficient data on the safety of the vaccine is available, which is expected in the third week of November, the application should be filed soon thereafter. So far, no serious safety concerns have been raised in the study.